GLP-1s have been increasingly adopted as a treatment for overweight and obesity, however their benefits go far beyond the scale. These medications can help improve key cardiometabolic biomarkers such as: blood sugar and cholesterol. While the evidence for this is clear, much of the existing data comes from clinical trials—leaving a gap in what we know about how these medications perform in the real-world, especially when prescribed and managed through telehealth. As telehealth platforms play an increasingly important role in weight management care, we sought to close that gap.
At the 2025 American Diabetes Association (ADA) Scientific Sessions, Ro shared new evidence demonstrating how patients receiving GLP-1 treatment on our platform improved their cardiometabolic health,which can help prevent chronic conditions like type 2 diabetes or hyperlipidemia.
In this study, we analyzed lab results from a sample of 131 patients who were prescribed semaglutide through the Body membership and completed both baseline and follow-up lab testing. All patients were on a maintenance dose of semaglutide (1.7 mg, 2.0 mg, or 2.4 mg) at the time of follow-up testing and received at least 10 refills of medication (approximating 1-year on the program).
What we found
Patients saw meaningful improvements in key cardiometabolic markers:
Patients who started the Body membership with abnormal lab values across these biomarkers experienced even greater improvements. The following percent improved their levels to normal ranges in follow-up testing:
The most compelling finding?
82% of patients with elevated HbA1c at baseline reverted to normoglycemia (a healthy blood sugar range) at their follow up testing.
Why this matters
This data reinforces what we’ve long believed: when GLP-1 treatment is paired with high-quality care and support at each step of the journey, patients can improve their health. The convenience of the Body membership, paired with data-driven clinical care, helps patients stay engaged and on track to progress towards their health goals.
Ro is making it easier for patients to reach their health goals—whether that’s losing weight, improving blood sugar, or reducing long-term risk for chronic disease.